Trial Profile
Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REPAIR
- 13 Jun 2022 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 13 Jun 2022 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 07 Jun 2021 Planned End Date changed from 29 Jun 2021 to 30 Jun 2023.